title: Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy.
abstract: Lipodystrophy with increased intra-abdominal fat in human immunodeficiency virus (HIV) infection is common in the era of highly active antiretroviral therapy. It contributes to the metabolic derangements, as it does in non-HIV-related conditions. Growth hormone administration reduces intra-abdominal fat content. This study compared the relative changes in omental-mesenteric (OMAT) and retroperitoneal adipose tissues (RPAT) during therapy with recombinant human growth hormone (rhGH) in HIV-associated lipodystrophy. Of 30 subjects who began rhGH therapy (6 mg/day), 25 completed 12 wk and 19 completed 24 wk. Fourteen subjects were followed for an additional 12 wk. Volumes of OMAT and RPAT were calculated from total body MRI scans and compared by paired t-tests. Both OMAT and RPAT significantly decreased after 12 and 24 wk of rhGH treatment (P < 0.001), but the reduction was more pronounced in OMAT than in RPAT (P < 0.001). Both OMAT and RPAT increased significantly (P < 0.001) after therapy was discontinued, but OMAT increased significantly more than did RPAT (122 vs. 37%, P < 0.001). There is preferential loss and regain of OMAT, compared with RPAT, in subjects with HIV-associated lipodystrophy undergoing growth hormone treatment.
authors.affiliation: Division of Gastroenterology, Obesity Research Center, St. Luke's-Roosevelt Hospital Center, New York, New York 10025, USA.
authors.forename: Qing
authors.initials: Q
authors.lastname: He
authors.forename: Ellen S
authors.initials: ES
authors.lastname: Engelson
authors.forename: Jeanine B
authors.initials: JB
authors.lastname: Albu
authors.forename: Steven B
authors.initials: SB
authors.lastname: Heymsfield
authors.forename: Donald P
authors.initials: DP
authors.lastname: Kotler
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects* / Q000473:pathology; D000328:Adult; D000886:Anthropometry; D001823:Body Composition / Q000187:drug effects; D013006:Growth Hormone / Q000627:therapeutic use*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D008066:Lipolysis / Q000187:drug effects; D008279:Magnetic Resonance Imaging; D008297:Male; D008643:Mesentery / Q000187:drug effects / Q000502:physiology*; D009852:Omentum / Q000187:drug effects / Q000502:physiology*
chemical_list: D013006:Growth Hormone